Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	QIAGEN	Acceleron Pharma	Novavax	argenx	Neurocrine Biosciences
Symbol	NYSE:QGEN	NASDAQ:XLRN	NASDAQ:NVAX	NASDAQ:ARGX	NASDAQ:NBIX
Price Information
Current Price	$53.38	$178.75	$141.86	$278.96	$80.69
50-Day Moving Average	$53.55	$175.42	$173.12	$295.57	$94.98
52-Week Low	$45.58	$108.82	$106.11	$248.21	$78.31
52-Week High	$59.00	$189.99	$331.68	$382.15	$120.27
MarketRank™
Overall Score	1.4	2.0	2.1	2.0	2.9
Analysis Score	1.3	2.1	3.3	4.4	4.3
Community Score	4.1	4.9	5.0	4.5	5.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	2.5	1.7	0.8	2.5
Earnings & Valuation Score	0.6	0.6	0.6	0.0	2.5
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Buy	Buy
Consensus Price Target	$52.13	$171.29	$249.60	$355.38	$116.47
% Upside from Price Target	-2.34% downside	-4.18% downside	75.95% upside	27.39% upside	44.34% upside
Trade Information
Market Cap	$12.17 billion	$10.93 billion	$10.73 billion	$14.37 billion	$7.65 billion
Beta	0.23	0.13	1.28	0.93	0.74
Average Volume	806,535	572,759	4,670,074	178,240	859,735
Sales & Book Value
Annual Revenue	$1.87 billion	$92.52 million	$475.60 million	$41.60 million	$1.05 billion
Price / Sales	6.51	118.15	22.55	345.45	7.32
Cashflow	$3.22 per share	N/A	N/A	N/A	$4.66 per share
Price / Cash	16.58	N/A	N/A	N/A	17.32
Book Value	$13.22 per share	$11.74 per share	$6.10 per share	$32.92 per share	$14.19 per share
Price / Book	4.04	15.23	23.26	8.47	5.69
Profitability
Net Income	$359.19 million	$-166.03 million	$-418.26 million	$-604.19 million	$407.30 million
EPS	$2.56	($4.21)	($14.81)	($7.43)	$4.57
Trailing P/E Ratio	20.85	N/A	N/A	N/A	17.66
Forward P/E Ratio	26.96	N/A	5.18	N/A	25.86
P/E Growth	1.89	N/A	N/A	N/A	N/A
Net Margins	26.61%	-226.01%	-89.31%	-73.28%	41.59%
Return on Equity (ROE)	20.71%	-32.11%	-149.66%	-24.48%	35.89%
Return on Assets (ROA)	10.20%	-29.45%	-45.23%	-20.69%	23.55%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.52	N/A	0.70	N/A	0.25
Current Ratio	1.90	12.14	1.24	11.74	4.45
Quick Ratio	1.58	12.14	1.24	11.50	4.34
Ownership Information
Institutional Ownership Percentage	52.02%	90.35%	52.77%	55.23%	95.30%
Insider Ownership Percentage	9.00%	1.70%	2.10%	N/A	4.30%
Miscellaneous
Employees	5,610	312	375	336	845
Shares Outstanding	227.99 million	61.16 million	75.61 million	51.52 million	94.87 million
Next Earnings Date	2/8/2022 (Estimated)	2/24/2022 (Estimated)	3/7/2022 (Estimated)	3/3/2022 (Estimated)	2/3/2022 (Estimated)
Optionable	Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	15 Best Stocks to Buy for 2022 According to Analysts finance.yahoo.com - December 6 at 12:43 PM
	Here's Why Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt Responsibly nasdaq.com - December 3 at 12:59 PM
	Neurocrine Biosciences (NASDAQ:NBIX) Cut to "Sell" at Zacks Investment Research marketbeat.com - December 2 at 2:30 AM
	Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer finance.yahoo.com - November 30 at 4:41 PM
	Neurocrine Biosciences (NASDAQ:NBIX) Hits New 52-Week Low at $83.66 americanbankingnews.com - November 30 at 12:44 PM
	Neurocrine Biosciences, Inc. Shares Near 52-Week Low - Market Mover nasdaq.com - November 30 at 6:40 AM
	Neurocrine Biosciences Enters Oversold Territory (NBIX) nasdaq.com - November 29 at 5:47 PM
	Thinking Of Selling Neurocrine Biosciences Inc. (NASDAQ: NBIX) Stock? Check This Out First stocksregister.com - November 27 at 1:16 PM
	Reviewing Sutro Biopharma (NASDAQ:STRO) & Neurocrine Biosciences (NASDAQ:NBIX) americanbankingnews.com - November 26 at 7:12 PM
	Neurocrine Biosciences Gets Promising Drugs in Licensing Deal gurufocus.com - November 24 at 12:01 PM
	Neurocrine Biosciences & Sosei Group Collaborate to Develop Treatment for Neuropsychiatric Disorders contractpharma.com - November 22 at 2:29 PM
	Neurocrine stocks up on a biotech's psychiatric drugs biopharmadive.com - November 22 at 2:29 PM
	Neurocrine Commits $2.6 Billion+ to Sosei Heptares, Neuropsychiatric Disorders pharmalive.com - November 22 at 2:29 PM
	Neurocrine Partners with Japanese Firm on Potential New Dementia Drug sdbj.com - November 22 at 2:29 PM
	Neurocrine Biosciences (NASDAQ:NBIX) Sets New 52-Week Low at $84.53 americanbankingnews.com - November 22 at 1:02 PM
	Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets fiercebiotech.com - November 22 at 9:29 AM
	Sosei Reaches Deal With Neurocrine On Neuropsychiatric Disorders; Eligible To Receive Up To $2.6 Bln markets.businessinsider.com - November 22 at 9:29 AM
	Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Recommendation of "Buy" by Analysts americanbankingnews.com - November 22 at 4:16 AM
	Neurocrine Biosciences (NASDAQ:NBIX) Upgraded at Zacks Investment Research marketbeat.com - November 20 at 1:24 AM
	First Week of NBIX January 2022 Options Trading nasdaq.com - November 19 at 5:39 PM
	Neurocrine Biosciences (NASDAQ:NBIX) Receives New Coverage from Analysts at BMO Capital Markets americanbankingnews.com - November 18 at 7:58 PM
	Analyst Ratings For Neurocrine Biosciences markets.businessinsider.com - November 17 at 12:42 PM
	Neurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Overweight at JPMorgan Chase & Co. americanbankingnews.com - November 17 at 9:04 AM
	Tag: Neurocrine Biosciences Inc. stocksregister.com - November 3 at 1:07 PM
	What 5 Analyst Ratings Have To Say About Neurocrine Biosciences benzinga.com - November 2 at 8:50 PM
	Notable Two Hundred Day Moving Average Cross - NBIX nasdaq.com - November 2 at 3:50 PM
	Neurocrine Reports Rising Earnings, Record Sales for Ingrezza sdbj.com - November 2 at 3:50 PM

Date	Company	Brokerage	Action
12/2/2021	argenx	Kepler Capital Markets	Upgrade
11/29/2021	argenx	Piper Sandler	Upgrade
11/26/2021	QIAGEN	Kepler Capital Markets	Downgrade
11/18/2021	Neurocrine Biosciences	BMO Capital Markets	Initiated Coverage
11/17/2021	Neurocrine Biosciences	JPMorgan Chase & Co.	Upgrade
11/2/2021	Neurocrine Biosciences	Citigroup	Lower Price Target
11/2/2021	Neurocrine Biosciences	Raymond James	Lower Price Target
11/2/2021	Neurocrine Biosciences	Royal Bank of Canada	Lower Price Target
11/2/2021	Neurocrine Biosciences	Mizuho	Boost Price Target
11/2/2021	Neurocrine Biosciences	Cantor Fitzgerald	Boost Price Target
10/28/2021	argenx	Guggenheim	Upgrade
10/28/2021	argenx	Raymond James	Upgrade
10/21/2021	QIAGEN	Norddeutsche Landesbank	Reiterated Rating
10/19/2021	argenx	Barclays	Upgrade
10/18/2021	Neurocrine Biosciences	SVB Leerink	Reiterated Rating
10/14/2021	QIAGEN	Redburn Partners	Initiated Coverage
10/14/2021	Neurocrine Biosciences	Morgan Stanley	Downgrade
10/6/2021	Acceleron Pharma	Jefferies Financial Group	Initiated Coverage
10/6/2021	argenx	Jefferies Financial Group	Initiated Coverage
10/4/2021	Acceleron Pharma	Raymond James	Downgrade
10/4/2021	argenx	Robert W. Baird	Boost Price Target
10/1/2021	Acceleron Pharma	Morgan Stanley	Reiterated Rating
10/1/2021	Acceleron Pharma	Barclays	Downgrade
9/30/2021	Acceleron Pharma	Cowen	Downgrade
9/30/2021	Acceleron Pharma	Morgan Stanley	Downgrade
9/30/2021	Acceleron Pharma	HC Wainwright	Downgrade
9/30/2021	Acceleron Pharma	Piper Sandler	Downgrade
9/30/2021	Acceleron Pharma	SVB Leerink	Boost Price Target
9/30/2021	Neurocrine Biosciences	HC Wainwright	Reiterated Rating
9/27/2021	Acceleron Pharma	Royal Bank of Canada	Boost Price Target
9/23/2021	argenx	Redburn Partners	Upgrade
9/22/2021	Neurocrine Biosciences	Needham & Company LLC	Initiated Coverage
9/7/2021	argenx	Morgan Stanley	Downgrade
9/2/2021	argenx	Barclays	Reiterated Rating
9/1/2021	Novavax	Chardan Capital	Reiterated Rating
8/6/2021	Neurocrine Biosciences	Canaccord Genuity	Downgrade
8/5/2021	Acceleron Pharma	Piper Sandler	Boost Price Target
8/4/2021	argenx	JPMorgan Chase & Co.	Reiterated Rating
8/4/2021	Neurocrine Biosciences	Morgan Stanley	Lower Price Target
8/3/2021	argenx	Morgan Stanley	Boost Price Target
7/23/2021	argenx	Deutsche Bank Aktiengesellschaft	Initiated Coverage
7/22/2021	argenx	Wedbush	Boost Price Target
7/21/2021	argenx	HC Wainwright	Reiterated Rating
7/19/2021	Acceleron Pharma	Wolfe Research	Initiated Coverage
7/16/2021	Neurocrine Biosciences	HC Wainwright	Reiterated Rating
7/14/2021	QIAGEN	Cheuvreux	Downgrade
7/14/2021	QIAGEN	Kepler Capital Markets	Downgrade
7/14/2021	QIAGEN	Citigroup	Lower Price Target
7/9/2021	QIAGEN	Kepler Capital Markets	Upgrade
6/27/2021	Acceleron Pharma	SVB Leerink	Reiterated Rating
6/25/2021	QIAGEN	DZ Bank	Reiterated Rating
6/24/2021	Acceleron Pharma	Oppenheimer	Boost Price Target
6/18/2021	argenx	UBS Group	Initiated Coverage
6/17/2021	QIAGEN	Deutsche Bank Aktiengesellschaft	Reiterated Rating
6/15/2021	Acceleron Pharma	SVB Leerink	Reiterated Rating
6/15/2021	Novavax	Cantor Fitzgerald	Boost Price Target
6/11/2021	QIAGEN	Berenberg Bank	Reiterated Rating
6/8/2021	QIAGEN	The Goldman Sachs Group	Reiterated Rating
6/8/2021	argenx	Wedbush	Lower Price Target
6/7/2021	argenx	Piper Sandler	Lower Price Target
6/3/2021	QIAGEN	The Goldman Sachs Group	Initiated Coverage
5/18/2021	Novavax	JPMorgan Chase & Co.	Reiterated Rating
5/18/2021	argenx	Morgan Stanley	Boost Price Target
5/18/2021	Neurocrine Biosciences	The Goldman Sachs Group	Initiated Coverage
5/16/2021	argenx	Kepler Capital Markets	Downgrade
5/12/2021	Novavax	B. Riley	Lower Price Target
5/12/2021	Novavax	Cantor Fitzgerald	Lower Price Target
5/12/2021	Novavax	HC Wainwright	Lower Price Target
5/12/2021	Novavax	JPMorgan Chase & Co.	Downgrade
5/11/2021	Novavax	Jefferies Financial Group	Lower Price Target
5/10/2021	argenx	HC Wainwright	Upgrade
5/6/2021	Neurocrine Biosciences	Wedbush	Lower Price Target
5/6/2021	Neurocrine Biosciences	Oppenheimer	Lower Price Target
5/6/2021	Neurocrine Biosciences	Morgan Stanley	Lower Price Target
5/6/2021	Neurocrine Biosciences	SVB Leerink	Lower Price Target
5/6/2021	Neurocrine Biosciences	Barclays	Upgrade
5/4/2021	QIAGEN	Deutsche Bank Aktiengesellschaft	Reiterated Rating
5/3/2021	Neurocrine Biosciences	Mizuho	Lower Price Target
4/26/2021	Neurocrine Biosciences	Mizuho	Lower Price Target
4/23/2021	argenx	Redburn Partners	Initiated Coverage
4/22/2021	QIAGEN	Deutsche Bank Aktiengesellschaft	Reiterated Rating
4/19/2021	argenx	Morgan Stanley	Lower Price Target
4/19/2021	Neurocrine Biosciences	Morgan Stanley	Boost Price Target
4/12/2021	Neurocrine Biosciences	Wedbush	Lower Price Target
4/7/2021	QIAGEN	DZ Bank	Reiterated Rating
4/2/2021	QIAGEN	Kepler Capital Markets	Reiterated Rating
4/1/2021	QIAGEN	DZ Bank	Reiterated Rating
3/29/2021	Acceleron Pharma	The Goldman Sachs Group	Reiterated Rating
3/29/2021	Acceleron Pharma	SVB Leerink	Reiterated Rating
3/23/2021	Acceleron Pharma	SVB Leerink	Downgrade
3/22/2021	Acceleron Pharma	The Goldman Sachs Group	Reiterated Rating
3/12/2021	Novavax	HC Wainwright	Boost Price Target
3/11/2021	Acceleron Pharma	Wolfe Research	Initiated Coverage
3/8/2021	argenx	Morgan Stanley	Boost Price Target
3/5/2021	argenx	Kepler Capital Markets	Reiterated Rating
3/5/2021	Neurocrine Biosciences	Robert W. Baird	Reiterated Rating
3/1/2021	Acceleron Pharma	Citigroup	Boost Price Target
2/26/2021	Acceleron Pharma	Piper Sandler	Boost Price Target
2/26/2021	Acceleron Pharma	Morgan Stanley	Boost Price Target
2/26/2021	Acceleron Pharma	SVB Leerink	Boost Price Target
2/19/2021	QIAGEN	Berenberg Bank	Reiterated Rating
2/17/2021	QIAGEN	Deutsche Bank Aktiengesellschaft	Reiterated Rating
2/10/2021	QIAGEN	Deutsche Bank Aktiengesellschaft	Reiterated Rating
2/5/2021	Novavax	Cantor Fitzgerald	Boost Price Target
2/1/2021	Novavax	B. Riley	Boost Price Target
1/29/2021	Acceleron Pharma	JPMorgan Chase & Co.	Boost Price Target
1/29/2021	Novavax	Cantor Fitzgerald	Boost Price Target
1/6/2021	QIAGEN	Norddeutsche Landesbank	Reiterated Rating
1/6/2021	QIAGEN	Nord/LB	Reiterated Rating
12/14/2020	QIAGEN	DZ Bank	Reiterated Rating
12/14/2020	Novavax	Jefferies Financial Group	Initiated Coverage
12/10/2020	QIAGEN	Exane BNP Paribas	Reiterated Rating
12/9/2020	QIAGEN	Deutsche Bank Aktiengesellschaft	Reiterated Rating
11/17/2020	Novavax	HC Wainwright	Lower Price Target
10/22/2020	Novavax	B. Riley	Lower Price Target
8/17/2020	Novavax	B. Riley	Reiterated Rating
8/5/2020	Novavax	LADENBURG THALM/SH SH	Downgrade
8/5/2020	Novavax	JPMorgan Chase & Co.	Upgrade
7/16/2020	Novavax	B. Riley	Boost Price Target
7/16/2020	Novavax	HC Wainwright	Boost Price Target
7/8/2020	Novavax	LADENBURG THALM/SH SH	Reiterated Rating
7/7/2020	Novavax	Cantor Fitzgerald	Boost Price Target
6/29/2020	Novavax	B. Riley	Boost Price Target
6/29/2020	Novavax	HC Wainwright	Boost Price Target
6/19/2020	Novavax	Cantor Fitzgerald	Boost Price Target

(Data available from 12/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources